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Introduction
Degradation of ECM that is present in the basement membrane 
and tumor stroma is essential for local invasion and formation 
of metastatic sites by malignant cancer cells (Kessenbrock et al., 
2010). Invadopodia, which were first described by Chen (1989), 
are ECM-degrading membrane protrusions formed on the ven-
tral surface of invasive cancer cells and are thought to play a 
role in cancer cell invasion (Yamaguchi et al., 2005b; Weaver, 
2006; Buccione et al., 2009; Madsen and Sahai, 2010). Invado-
podia have been observed in a variety of invasive cancer cell lines, 
including mammary adenocarcinoma, colon carcinoma, mela-
noma, and glioma as well as in primary invasive tumor cells de-
rived from glioblastoma and head and neck cancers (Clark et al., 
2007; Stylli et al., 2008). In the case of breast cancer cell lines, the 
ability to form invadopodia is closely related to their invasive and 
metastatic properties in vivo (Coopman et al., 1998; Yamaguchi 
et al., 2005a, 2009). Additionally, invadopodia-like protrusions 
in breast cancer cells have been observed during intravasation by 
intravital imaging (Condeelis and Segall, 2003; Yamaguchi   
et al., 2005b). A recent study showed that invasive cancer 
cells use invadopodia to breach the basement membrane and 
penetrate into the stroma (Schoumacher et al., 2010). More-
over, Eckert et al. (2011) recently reported that Twist, an   
inducer of epithelial–mesenchymal transition, induces invado-
podia formation to promote tumor metastasis and provided 
evidence of invadopodia formation in vivo in sections of inva-
sive primary tumors.
Many components of invadopodia, such as various pro-
teins involved in actin polymerization, cell signaling, mem-
brane trafficking, cell–ECM adhesion, and ECM degradation, 
have been reported to date (Linder, 2007; Gimona et al., 2008; 
Caldieri and Buccione, 2010). We and other researchers pre-
viously reported that invadopodia formation is induced by 
stimulation with serum and growth factors (Tague et al., 2004; 
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nvadopodia are extracellular matrix–degrading pro-
trusions  formed  by  invasive  cancer  cells  that  are 
thought to function in cancer invasion. Although many 
invadopodia components have been identified, signaling 
pathways  that  link  extracellular  stimuli  to  invadopodia 
formation remain largely unknown. We investigate the 
role of phosphoinositide 3-kinase (PI3K) signaling during 
invadopodia  formation.  We  find  that  in  human  breast 
cancer cells, both invadopodia formation and degrada-
tion of a gelatin matrix were blocked by treatment with 
PI3K inhibitors or sequestration of D-3 phosphoinositides. 
Functional analyses revealed that among the PI3K family 
proteins, the class I PI3K catalytic subunit p110, a fre-
quently mutated gene product in human cancers, was selec-
tively involved in invadopodia formation. The expression of 
p110 with cancerous mutations promoted invadopodia-
mediated  invasive  activity.  Furthermore,  knockdown  or 
inhibition of PDK1 and Akt, downstream effectors of PI3K 
signaling, suppressed invadopodia formation induced by 
p110 mutants. These data suggest that PI3K signaling 
via p110 regulates invadopodia-mediated invasion of 
breast cancer cells.
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Results
PI3K activity is required for invadopodia 
formation in human breast cancer cells
The formation of invadopodia in human cancer cells and podo-
somes, which are structures functionally similar to invadopodia, 
in  Src-transformed  fibroblasts  requires  the  activity  of  PI3K   
(Nakahara et al., 2003; Mandal et al., 2008; Oikawa et al., 2008). 
In the present study, the role of PI3K in invadopodia formation 
was investigated in detail in the highly invasive human breast 
cancer cell line MDA-MB-231 (Neve et al., 2006). MDA-MB-231 
cells form invadopodia in vitro and have, therefore, been widely 
used in studies investigating various aspects of these invasive 
structures (Chen et al., 1994). MDA-MB-231 cells were seeded 
onto fluorescent gelatin-coated coverslips in the presence or 
absence of each of two PI3K inhibitors, LY294002 and wort-
mannin, and stained for two invadopodia markers, cortactin and 
F-actin. Invadopodia were observed as dotlike clusters of cortactin 
and F-actin on the ventral membrane of cells, which corresponded 
with the degradation sites on the gelatin matrix (Fig. S1 A). To 
quantify the invadopodia-mediated degradation of the gelatin 
matrix for each treatment, we calculated the area of the degra-
dation sites. Both LY294002 and wortmannin significantly in-
hibited the formation of invadopodia and gelatin degradation in 
a dose-dependent manner, with half-maximal inhibitory con-
centration (IC50) values of 3.3 µM and 3.6 nM for LY294002 
and wortmannin, respectively (Fig. S1, B–D). Furthermore, the 
percentage of cells with invadopodia and the number of invado-
podia per cell were also reduced in cells treated with either 
PI3K inhibitor (Fig. S1, E and F).
We also examined the effect of PI3K inhibition on the sta-
bility of preformed invadopodia. MDA-MB-231 cells express-
ing GFP-actin were seeded onto plates coated with a gelatin 
matrix, and cells were observed using time-lapse microscopy 
upon treatment with LY294002. LY294002 treatment of cells 
exhibiting GFP-actin–positive invadopodia resulted in the deg-
radation of invadopodia within 1 min of treatment (Fig. S1 G 
and Video 1). A similar result was obtained when cells express-
ing Venus-cortactin were analyzed in the same manner (Video 2). 
Quantification of the intensity of GFP-actin signals at the inva-
dopodia revealed that the actin core structures of invadopodia 
disassembled immediately after the addition of LY294002, 
whereas the invadopodia of cells treated with DMSO did not 
disassemble (Fig. S1 H). Collectively, these results indicate that 
PI3K activation is required for both the formation and stabil-
ity of invadopodia in human breast cancer cells.
D-3 phosphoinositides are required  
for invadopodia formation
We next investigated the role of D-3 phosphoinositides synthe-
sized by PI3Ks in invadopodia formation. The pleckstrin ho-
mology (PH) domain of Akt interacts with phosphatidylinositol 
3,4,5-trisphosphate  (PI(3,4,5)P3)  and  phosphatidylinositol 
3,4-bisphosphate (PI(3,4)P2), which are two major products of 
PI3K, and its overexpression results in the sequestration and 
inhibition of the function of these phosphoinositides (Várnai   
et al., 2005). In the present study, the PH domain of Akt was 
Yamaguchi et al., 2005a; Mandal et al., 2008; Eckert et al., 2011). 
However, the signaling pathways that link these extracellular 
stimuli to invadopodia formation remain largely unknown.
The phosphoinositide 3-kinases (PI3Ks) are a family of 
lipid kinases that phosphorylate phosphoinositides at the D-3 
position of the inositol headgroup and, thus, produce D-3 
phosphoinositides (Cantley, 2002). PI3Ks mediate the signal 
transduction of extracellular stimuli and regulate diverse cel-
lular events, such as mitogenesis, survival, membrane trans-
port, and cell migration (Engelman et al., 2006; Cain and 
Ridley, 2009). PI3Ks are subdivided into three general classes 
(I–III) in mammals on the basis of their enzyme domain struc-
tures and substrate specificities (Fruman et al., 1998). Specifi-
cally, the class I subfamily consists of four catalytic subunits, 
including three class IA subunits (p110, p110, and p110) 
and a single class IB subunit (p110). However, the class II 
PI3K group consists of three isoforms, PI3K-C2, PI3K-C2, 
and PI3K-C2. Finally, mammals have a single class III iso-
form, namely, Vps34, which is a homologue of the sole PI3K 
present in yeast.
Uncontrolled activation of the PI3K signaling pathway 
leads to several pathological phenomena, including tumori-
genesis  and  tumor  malignancy  (Cantley,  2002). This  is  in-
dicated by the finding that the expression and activity of several 
members of the PI3K signaling pathway are frequently altered 
in a variety of human cancers (Yuan and Cantley, 2008). For 
instance, the PIK3CA gene, which encodes the class IA PI3K 
catalytic subunit p110, is one of the most frequently ampli-
fied and mutated genes identified in human cancers (Yuan and 
Cantley, 2008; Zhao and Vogt, 2008). Clinical studies involv-
ing  human  breast  cancer  patients  revealed  that  mutations 
leading to the activation of PIK3CA are associated with the 
development of invasive and metastatic phenotypes and poor 
patient prognosis (Saal et al., 2005; Li et al., 2006; Maruyama 
et al., 2007). Moreover, a previous study has shown that intro-
duction of the mutant PIK3CA gene into a breast cancer cell 
line  enhanced  lung  metastasis  in  mice  (Pang  et  al.,  2009). 
However, the detailed mechanisms by which the PIK3CA gene 
product p110 contributes to cancer invasion and metastasis 
are yet to be determined.
It is established that 3-phosphoinositide–dependent pro-
tein kinase-1 (PDK1) is a serine/threonine kinase that mediates 
PI3K signaling during various cellular responses (Toker and 
Newton, 2000). PDK1 is recruited to cell membranes upon 
PI3K activation, where it phosphorylates and activates Akt, the 
major mediator of the PI3K signaling pathway (Stephens et al., 
1998). Both PDK1 and Akt are overexpressed in human breast 
cancers and are thought to be critical components of the onco-
genic PI3K signaling pathway (Dillon et al., 2007; Maurer   
et al., 2009; Sheng et al., 2009). Furthermore, previous studies 
have demonstrated that PDK1 and Akt are involved in the inva-
sive and metastatic phenotypes of human cancer cells (Xie   
et al., 2006; Dillon et al., 2007; Liu et al., 2009; Sheng et al., 
2009). However, the roles of PDK1 and Akt in invadopodia for-
mation remain unclear. In the present study, we investigate the 
role of PI3K signaling during invadopodia formation in invasive 
human breast cancer cells.1277 PI3-kinase p110 regulates invadopodia formation • Yamaguchi et al.
PCR  and  standard  semiquantitative  PCR  analyses  performed   
using different sets of primers specific for the PI3K isoforms 
(Fig. 2 A and Fig. S3 A). The class I subunits p110, p110, and 
p110, the class II subunit C2, and the class III subunit Vps34 
were abundantly expressed in these cells. Furthermore, the ex-
pression of the class II subunit C2 was weak but detectable. 
However, these cells did not express the class I subunit p110 or 
the class II subunit C2.
siRNA knockdown experiments were performed to deter-
mine the contribution of individual PI3K isoforms to invado-
podia formation. MDA-MB-231 cells were transfected with 
siRNAs targeting each PI3K enzyme and subsequently examined 
for invadopodia formation and gelatin degradation. The effi-
ciency and selectivity of the siRNAs in knocking down individual 
PI3K isoforms were confirmed by RT-PCR analysis (Fig. 2 B), 
and the knockdown of class I p110 enzymes was also confirmed 
by immunoblotting (Fig. 2 C). Cells with reduced p110 levels 
showed a significant decrease in invadopodia formation and 
gelatin degradation activity (Fig. 2, D–G). Similar results were 
obtained with three other siRNAs targeting different regions of 
the p110 gene (Fig. S4, A and B). However, cells transfected 
with siRNAs targeting other class I PI3K enzymes (i.e., p110 
and p110) did not show decreased invadopodia formation or 
gelatin degradation activity (Fig. 2, D and E). Furthermore, 
knockdown of classes II and III PI3Ks, including C2, C2, 
and Vps34, did not affect gelatin degradation activity (Fig. 2 D). 
Examination of the localization of endogenous p110 by immuno-
cytochemistry revealed the presence of strong signals corre-
sponding  to  endogenous  p110  at  invadopodia  that  were 
overexpressed in MDA-MB-231 cells as a GFP fusion protein 
(GFP-Akt-PH). This construct, which localized to the plasma 
membrane, inhibited the formation of invadopodia, as measured 
by both the percentage of cells with invadopodia and the num-
ber of invadopodia per cell, and gelatin degradation (Fig. 1, A–D). 
In contrast, a mutant form of the Akt PH domain (R25C), in 
which an essential amino acid for phosphoinositide binding is 
mutated (Várnai et al., 2005), did not localize to the plasma 
membrane or inhibit gelatin degradation (Fig. 1, A and B). Fur-
thermore, to examine the localization of D-3 phosphoinositides 
at invadopodia sites, a cell line expressing the GFP-Akt-PH 
construct at an extremely low level, 13 times less than tran-
sient expression (Fig. S2 A), was established, which allows the 
cells to retain invadopodia. In these cells, signals corresponding 
to GFP-Akt-PH were significantly concentrated at F-actin–rich 
invadopodia and at the gelatin degradation sites (Fig. 1 E). This 
accumulation of GFP signals at invadopodia was not observed 
when cells expressing GFP alone were examined in the same 
manner (Fig. S2 B). These results indicate that PI(3,4,5)P3 and/or 
PI(3,4)P2 produced as downstream effectors of PI3K have an 
essential role in invadopodia-mediated ECM degradation.
The class I PI3K catalytic subunit  
p110 is an essential regulator of 
invadopodia formation
Mammalian cells contain eight PI3K enzymes, which are further 
classified into classes I, II, and III (Fruman et al., 1998). In the 
present study, the expression levels of the PI3K family of proteins 
were examined in MDA-MB-231 cells by real-time quantitative 
Figure 1.  D-3 phosphoinositides are necessary for invadopodia formation. (A) MDA-MB-231 cells transfected with the GFP, GFP-Akt-PH wild-type (WT), 
or GFP-Akt-PH R25C mutant construct were cultured on fluorescent gelatin-coated coverslips for 7 h and imaged by confocal microscopy. Arrowheads 
denote degradation sites on the gelatin matrix. (B–D) Degraded areas on the gelatin matrix (B), the percentage of cells with invadopodia (C), and the 
relative number of invadopodia per cell (D) were quantified for transfected cells as described in the Materials and methods. (E) MDA-MB-231 cells stably 
expressing GFP-Akt-PH WT were cultured on fluorescent gelatin-coated coverslips for 3 h, stained for F-actin, and observed by confocal microscopy. Insets 
are magnified images of the boxed regions. Arrowheads denote invadopodia where GFP-Akt-PH signals were accumulated. Data in B–D are represented 
as means + SEM of four independent determinations. *, P < 0.01; and **, P < 0.005 by Student’s t test.JCB • VOLUME 193 • NUMBER 7 • 2011   1278
involved in invadopodia-mediated invasion of human breast 
cancer cells.
The effect of p110 knockdown on invadopodia formation 
was assessed in other invasive breast cancer cell lines, namely 
BT-549 and Hs578T. BT-549 cells treated with two different 
p110 siRNAs showed a significant decrease in invadopodia-
mediated gelatin degradation (Fig. S4, C and D). As Hs578T 
cells were sensitive to siRNA transfection under the present   
enriched with F-actin and were associated with gelatin degrada-
tion sites (Fig. 2 H). To ascertain whether invadopodia forma-
tion mediated by p110 reflects the invasiveness of cancer cells, 
an in vitro Matrigel invasion assay was performed. MDA-MB-231 
cells transfected with p110 siRNA showed markedly reduced 
invasion through Matrigel in comparison to cells transfected 
with control siRNA (Fig. 2 I). Collectively, these results indi-
cate that among the PI3K family proteins, p110 is specifically 
Figure 2.  Class I PI3K catalytic subunit p110 is an essential regulator of invadopodia formation. (A) Real-time quantitative PCR analysis of the expres-
sion of PI3K isoforms in MDA-MB-231 cells. The relative mRNA levels of PI3K isoforms normalized with the mRNA levels of cyclophilin B are shown.   
(B and C) MDA-MB-231 cells were transfected with siRNAs targeting individual PI3K isoforms for 48 h, and the expression profiles of PI3K isoforms were 
determined by RT-PCR (B) and immunoblot analyses (C). Cyclophilin B (Cycl) and -actin were used as internal controls. (D) MDA-MB-231 cells transfected 
with the indicated siRNAs were cultured on fluorescent gelatin-coated coverslips for 7 h, and the degraded areas on the gelatin matrix were quantified.   
(E) Representative images of cells transfected with siRNAs targeting p110 isoforms and stained for F-actin. Arrowheads denote the gelatin degradation sites.   
(F and G) The percentage of cells with invadopodia (F) and the relative number of invadopodia per cell (G) were determined in cells transfected with control or 
p110 siRNA. (H) MDA-MB-231 cells plated onto fluorescent gelatin-coated coverslips for 4 h were stained with anti-p110 antibody and phalloidin. Insets   
are magnified images of the boxed regions. Arrowheads denote accumulation of p110 signals at invadopodia. (I) MDA-MB-231 cells transfected with 
control or p110 siRNA were labeled with CellTracker green and analyzed for invasion through Matrigel-coated Transwell inserts for 24 h. Invaded cells 
were then imaged by fluorescent microscopy and counted. Arrowheads denote invaded cells. Smaller dots represent pores of the membrane of Transwell 
inserts. (J) MDA-MB-231 cells transfected with the indicated siRNAs were serum-starved overnight and stimulated with 8 nM EGF for 10 min. The cells were 
then analyzed by immunoblotting to determine the phosphorylation status of Akt (p-Akt) and ERK (p-ERK). Data are represented as means + SEM of three 
(A and I), eight (D), and five (F and G) independent determinations. *, P < 0.01; and **, P < 0.0002 by Student’s t test.1279 PI3-kinase p110 regulates invadopodia formation • Yamaguchi et al.
gelatin-coated coverslips in the presence of PIK-75, TGX-221, 
or IC87114, which are selective inhibitors of p110, , and , 
respectively (Knight et al., 2006; Chaussade et al., 2007). p110 
inhibition by PIK-75 treatment significantly inhibited gelatin 
degradation in a dose-dependent manner, showing an IC50 of 
25.0 nM (Fig. 3, A–C), and suppressed invadopodia formation 
(Fig. 3, D and E). A similar inhibition of gelatin degradation was 
observed when BT-549 and Hs578T breast cancer cells were 
treated with PIK-75 (Fig. S4, H and I). However, neither TGX-221 
nor IC87114 significantly affected gelatin degradation (Fig. 3, 
A and C) despite their use at concentrations well above the IC50 
values reported previously (Chaussade et al., 2007). PIK-75 
treatment also markedly inhibited Matrigel invasion of MDA-
MB-231 cells (Fig. 3 F).
As expected, we found that only p110 inhibition by PIK-75 
suppressed EGF-induced Akt phosphorylation (Fig. 3 G). In ad-
dition, EGF-induced phosphorylation of ERK was not affected 
by PIK-75 treatment (Fig. 3 G). At the concentrations used in 
these  experiments,  PIK-75  should  specifically  inhibit  p110  
activity but should not block p110 and p110 activities based 
on results of previous studies (Knight et al., 2006; Chaussade   
et al., 2007). These results indicate that p110 plays a pivotal 
role in PI3K signaling and regulates the invadopodia-mediated 
ECM degradation activity of invasive breast cancer cells.
experimental conditions, a short hairpin RNA (shRNA) targeting 
the p110 gene was introduced into Hs578T cells by lentiviral 
transduction. Transduction of Hs578T cells with p110 shRNA 
resulted in a marked reduction of the expression of p110 and a 
concomitant decrease in gelatin degradation activity as com-
pared with cells with control shRNA (Fig. S4, E–G).
The PI3K signaling pathway activation status was deter-
mined by measuring the amount of phosphorylated Akt, a major 
downstream effector of the PI3K signaling pathway. Knockdown 
of p110 suppressed Akt phosphorylation upon EGF stimulation 
(Fig. 2 J), whereas knockdown of p110 or p110 had almost no 
effect. Thus, p110 is likely the primary mediator of growth 
factor–stimulated PI3K signaling in this cell type. Importantly, 
EGF-induced phosphorylation of ERK was not affected by 
p110 knockdown (Fig. 2 J). This result suggests that p110 in-
hibition does not affect MAPK signaling, a pathway that has 
been implicated in invadopodia formation in human melanoma 
cells (Tague et al., 2004).
Pharmacological inhibition of p110 blocks 
invadopodia formation
To confirm that p110 is an essential regulator of invadopodia 
formation, the effect of selective inhibitors of class I PI3K   
isoforms was investigated. Cells were cultured on fluorescent 
Figure 3.  Effects of pharmacological inhibition of class I PI3Ks on invadopodia formation. (A) MDA-MB-231 cells were cultured on fluorescent gelatin-
coated coverslips for 7 h in the presence or absence of various class I PI3K inhibitors, including PIK-75 for p110, TGX-221 for p110, and IC87114 for 
p110. The degraded areas on the gelatin matrix were quantified and are represented as the percentage of control DMSO-treated cells. (B) Dose–response 
curve of gelatin degradation obtained in the presence of increasing concentrations of PIK-75 is shown. (C) Representative images of MDA-MB-231 cells 
treated with various class I PI3K inhibitors are shown. Arrowheads denote the gelatin degradation sites. (D and E) The percentage of cells with invado-
podia (D) and the relative number of invadopodia per cell (E) were determined in cells treated with control DMSO or 100 nM PIK-75. (F) MDA-MB-231 
cells labeled with CellTracker green were analyzed for invasion through Matrigel-coated Transwell inserts in the presence or absence of 100 nM PIK-75 for 24 h. 
Invaded cells were then imaged by fluorescent microscopy and counted. Arrowheads denote invaded cells. (G) MDA-MB-231 cells were serum-starved 
overnight and treated with 300 nM of the indicated class I PI3K inhibitors for 1 h. The cells were subsequently stimulated with 8 nM EGF for 10 min and 
used for immunoblotting to determine the phosphorylation status of Akt (p-Akt) and ERK (p-ERK). Data are represented as means ± SEM of six (A, D, and E) 
and three (B and F) independent determinations. *, P < 0.01; and **, P < 0.0005 by Student’s t tests.JCB • VOLUME 193 • NUMBER 7 • 2011   1280
Akt3) was detected in MDA-MB-231 cells by real-time quanti-
tative PCR (Fig. S3 B). To avoid possible functional redun-
dancy, all Akt isoforms were simultaneously knocked down. In 
cells transfected with two different sets of siRNAs, the expres-
sion of total Akt was efficiently suppressed (Fig. 5 E). Akt 
knockdown significantly decreased invadopodia formation and 
gelatin degradation (Fig. 5, F–H). Furthermore, knockdown of 
PDK1  or Akt  markedly  decreased  invadopodia  formation  in 
both E545K and H1047R p110 cells (Fig. 5 I). Examination of 
the localization of endogenous Akt and PDK1 proteins revealed 
that these proteins accumulated at invadopodia-mediated gela-
tin degradation sites in MDA-MB-231 cells (Fig. 5 J) and 
BT549 cells (Fig. S4 J). These results indicate that the role of 
PDK1 and Akt as downstream targets of p110 is essential for 
invadopodia formation.
Pharmacological inhibition of PDK1 and 
Akt blocks invadopodia formation
To further confirm the involvement of PDK1 and Akt, cells 
were treated with OSU-03012 and the Akt inhibitor VIII, which 
are inhibitors of PDK1 and Akt, respectively. Although its 
specificity may need better characterization, OSU-03012 was 
shown to potently inhibit PDK1 activity by competing with 
ATP (Zhu et al., 2004). The Akt inhibitor VIII is a PH domain–
dependent specific Akt inhibitor and blocks activation of Akt 
(Barnett et al., 2005). Treatment of cells with these inhibitors 
resulted in a decrease in the levels of phosphorylated Akt   
(Fig. 6, A and B). These inhibitors markedly blocked gelatin 
degradation activity (IC50 = 3.9 µM for OSU-03012 and 2.2 µM 
for Akt inhibitor VIII; Fig. 6, C–F) and invadopodia formation 
(Fig. 6, G–J). We also examined the effect of a PKC inhibitor 
on invadopodia formation because PKC is another major sub-
strate of PDK1 (Toker and Newton, 2000). When treated with 
the broad-range PKC inhibitors calphostin and GF109203X, 
MDA-MB-231 cells showed no obvious changes in gelatin 
degradation activity (Fig. 6 C). Moreover, OSU-03012 and 
the Akt inhibitor VIII significantly blocked gelatin degra-
dation activities of cells expressing the activating mutants of 
p110 (Fig. 6 K).
Overexpression of Akt constructs affects 
invadopodia formation
The effect of the ectopic expression of various Akt constructs 
was examined by generating MDA-MB-231 cell lines stably 
expressing WT, kinase dead (KD), or a membrane-targeted 
constitutively active form (myristoylated [Myr]) of Akt1. Akt 
phosphorylation increased in cells expressing WT Akt1 but 
decreased in cells expressing KD Akt1 in comparison to con-
trol mock-infected cells (Fig. 7 A). Myr Akt1 expression ro-
bustly enhanced Akt phosphorylation (Fig. 7 A). Invadopodia 
formation and gelatin degradation activity were increased in 
WT Akt1 cells but decreased in KD Akt1 cells, which is con-
sistent with the changes in Akt phosphorylation (Fig. 7, B–E). Un-
expectedly, however, cells expressing Myr Akt1 showed a 
marked decrease in invadopodia formation and gelatin degradation 
(Fig. 7, B–E). Ectopically expressed WT Akt1 accumulated at 
invadopodia in a similar manner to endogenous protein (Fig. 7 F). 
Activating mutations in the PIK3CA gene 
promote invadopodia formation
The PIK3CA gene, which encodes p110, is one of the most 
frequently mutated genes in human breast cancers, and muta-
tions in this gene are associated with invasion and metastasis 
(Saal et al., 2005; Maruyama et al., 2007). Most of the muta-
tions occur at two hot spots, namely E545K in the helical do-
main and H1047R in the catalytic domain. These mutations 
constitutively activate the PI3K signaling pathway (Isakoff   
et al., 2005; Kang et al., 2005). Accordingly, the effect of these 
PIK3CA mutations on invadopodia formation was investigated 
in MDA-MB-231 cells, which express wild-type (WT) p110 
(Hollestelle et al., 2007). MDA-MB-231 cell lines stably ex-
pressing WT, E545K, or H1047R p110 were generated. The 
expression levels of the ectopic proteins were 4–5 times 
higher than the expression level of the endogenous protein   
(Fig. 4 A). The results showed an increase in EGF-induced Akt 
phosphorylation in cells expressing WT p110 and a further in-
crease in cells expressing either E545K or H1047R p110 in 
comparison to control mock-infected cells (Fig. 4 B). Further-
more, morphological analysis revealed that WT p110 cells 
tended to form more lamellipodia or membrane ruffles than 
control mock-infected cells (Fig. 4 C). An additional increase in 
the  protrusive  activities  in  E545K-  and  H1047R-expressing 
cells was observed (Fig. 4 C), which may reflect enhanced cell 
motility induced by these p110 mutants as described previ-
ously (Pang et al., 2009). Invadopodia formation and gelatin 
degradation activity were moderately increased in WT p110 
cells and further enhanced in E545K- and H1047R-expressing 
cells (Fig. 4, D–G). The enhanced gelatin degradation activity 
in E545K- and H1047R-expressing cells was still sensitive to 
PIK-75 treatment, indicating that the enzymatic activity is cru-
cial for invadopodia formation (Fig. 4 H). Similar to the behav-
ior of the endogenous protein, the E545K and H1047R p110 
mutants also accumulated at gelatin degradation sites (Fig. 4 I). 
In addition, E545K- and H1047R-expressing cells showed en-
hanced invasion through Matrigel compared with mock-infected 
cells (Fig. 4 J). These findings indicate that these activating 
mutations in the PIK3CA gene commonly present in human 
cancers promote the invadopodia-mediated invasive activity of 
breast cancer cells.
PDK1 and Akt are involved  
in invadopodia formation
To  determine  the  downstream  target  of  p110  associated 
with invadopodia formation, the role of PDK1 was examined. 
PDK1 has been shown to translocate to the plasma membrane 
upon  activation  of  PI3Ks,  and  phosphorylate  downstream 
targets, including Akt (Toker and Newton, 2000). PDK1 ex-
pression in MDA-MB-231 cells was confirmed by immuno-
blotting and suppressed by two different siRNA sequences 
that target different regions of the PDK1 gene (Fig. 5 A). 
PDK1 down-regulation clearly impaired invadopodia forma-
tion in these cells and the related gelatin matrix degradation 
(Fig. 5, B–D).
The role of Akt in invadopodia formation was then exam-
ined. The expression of all Akt isoforms (i.e., Akt1, Akt2, and 1281 PI3-kinase p110 regulates invadopodia formation • Yamaguchi et al.
Akt1  mutants  markedly  increased Akt  phosphorylation,  it 
abrogated invadopodia-mediated gelatin degradation activity 
(Fig. S5, A and B). Collectively, these results confirm the role 
of Akt in invadopodia formation and suggest that site-specific 
and proper activation of Akt is necessary for efficient assembly 
of invadopodia.
In  contrast,  Myr Akt1  uniformly  distributed  throughout  the 
plasma membrane and showed no specific localization (Fig. 7 F). 
We also generated MDA-MB-231 cell lines expressing other 
constitutively active forms of Akt1, namely E17K and E40K, 
which have a higher affinity for phosphoinositides (Aoki et al., 
1998; Carpten et al., 2007). Although the expression of these 
Figure 4.  Cancerous p110 mutations promote invadopodia formation. (A) MDA-MB-231 cells stably expressing wild-type (WT), E545K, or H1047R 
p110 were analyzed by immunoblotting. Numbers below represent relative expression levels of the p110 constructs. (B) Cell lines stably expressing 
p110 were serum-starved overnight and stimulated with 8 nM EGF for 10 min. The phosphorylation status of Akt (p-Akt) was determined by immuno-
blotting. (C) Phase-contrast images show the morphology of the p110 cell lines. Arrowheads denote membrane protrusions. (D) Cells stably expressing 
the p110 constructs were cultured on fluorescent gelatin matrices for 7 h and stained with phalloidin to visualize invadopodia. Arrowheads denote 
the gelatin degradation sites. (E–G) Gelatin degradation activity (E), the percentage of cells with invadopodia (F), and the number of invadopodia per 
cell (G) were determined in p110 cell lines. (H) Cells expressing E545K or H1047R p110 were examined for gelatin degradation in the presence or 
absence of 100 nM PIK-75. (I) Cells expressing E545K or H1047R p110 were cultured on fluorescent gelatin matrices for 4 h and stained with anti-HA 
antibody to visualize localization of E545K and H1047R p110. Insets are magnified images of the boxed regions. Arrowheads denote colocalization 
of the HA signals with the gelatin degradation sites. (J) Cells labeled with CellTracker green were analyzed for invasion through Matrigel-coated Transwell 
inserts for 24 h. Data are represented as means + SEM of seven (E), six (F–H), and three (J) independent determinations. *, P < 0.05; **, P < 0.01; and   
***, P < 0.001 by Student’s t tests.JCB • VOLUME 193 • NUMBER 7 • 2011   1282
invadopodia formation. Although the predominant product of 
PI3K is PI(3,4,5)P3, several evidence raise the possibility that 
PI(3,4)P2 also plays a significant and redundant role in invado-
podia formation in parallel with PI(3,4,5)P3 (Fig. 8). Chuang   
et al. (2004) reported that siRNA knockdown of synaptojanin-2, 
which generates PI(3,4)P2 via dephosphorylation of PI(3,4,5)P3, 
blocks  invadopodia  formation  in  glioma  cells.  Moreover, 
Oikawa et al. (2008) reported that PI(3,4)P2 regulates podosome 
formation by recruiting Tks5 and N-WASP, which are essential 
components of podosomes. Therefore, although further studies 
are required to precisely define the individual roles of PI(3,4,5)P3 
and PI(3,4)P2, our results indicate that these D3-phosphoinositides 
Discussion
In the present study, the PI3K inhibitors LY294002 and wort-
mannin were shown to effectively inhibit invadopodia for-
mation in MDA-MB-231 human breast cancer cells. This 
result is consistent with the previous studies describing that 
the formation of invadopodia in human cancer cells and podo-
somes  in  Src  transformed  fibroblasts  requires  the  activity   
of PI3K (Nakahara et al., 2003; Mandal et al., 2008; Oikawa 
et al., 2008).
Overexpression of the Akt-PH domain, which sequesters 
the PI3K products PI(3,4,5)P3 and PI(3,4)P2, effectively blocked 
Figure 5.  PDK1 and Akt are essential downstream effectors of p110 for invadopodia formation. (A) MDA-MB-231 cells were transfected with control 
or two distinct PDK1 siRNAs for 48 h and used for immunoblotting to determine the amount of PDK1. (B–D) Cells transfected with the control or PDK1 
siRNA were cultured on fluorescent gelatin-coated coverslips for 7 h. Degraded areas on the gelatin matrix (B), the percentage of cells with invadopodia (C),   
and the number of invadopodia per cell (D) were quantified for transfected cells. (E) Cells were transfected with control or two different sets of siRNAs 
targeting Akt1, 2, and 3 for 48 h and used for immunoblotting analysis with the anti–pan-Akt antibody. (F–H) Degraded areas on the gelatin matrix (F), the 
percentage of cells with invadopodia (G), and the number of invadopodia per cell (H) were quantified for siRNA-transfected cells. (I) Cells stably express-
ing E545K or H1047R p110 were transfected with indicated siRNAs for 48 h and tested for invadopodia activities for 7 h. (J) MDA-MB-231 cells plated 
onto fluorescent gelatin-coated coverslips for 4 h were stained with the anti-Akt or anti-PDK1 antibody. Insets are magnified images of the boxed regions. 
Arrowheads denote the accumulation of Akt and PDK1 signals at the gelatin degradation sites. Data are represented as means + SEM of six (B, G, and H), 
four (C, D, and I), and three (F) independent determinations. *, P < 0.02; and **, P < 0.005 by Student’s t tests.1283 PI3-kinase p110 regulates invadopodia formation • Yamaguchi et al.
et al., 2006; Oser et al., 2009). The finding that treatment of 
cells with PI3K inhibitors blocked the formation of F-actin and 
cortactin structures of invadopodia suggests that PI3K signaling 
is involved in the first step of invadopodia formation. In support 
of this hypothesis, PI3K inhibitors disassembled the F-actin 
structures of invadopodia, as shown by time-lapse analysis, and 
produced by PI3K activity play an essential role in invado-
podia biogenesis.
We and other researchers have previously reported that in-
vadopodia formation is initiated with the assembly of actin core 
structures followed by the accumulation of matrix metallopro-
teinases for ECM degradation (Yamaguchi et al., 2005a; Artym 
Figure 6.  Pharmacological inhibition of PDK1 and Akt blocks invadopodia formation. (A and B) MDA-MB-231 cells were serum-starved overnight and 
treated with inhibitors, 10 µM OSU-03012 for PDK1 (A) or 20 µM Akt inhibitor VIII (Akt i VIII) for Akt (B) for 1 h. The cells were subsequently stimulated 
with 8 nM EGF for 10 min and used for immunoblotting to determine the phosphorylation status of Akt (p-Akt). (C) MDA-MB-231 cells were cultured on 
fluorescent gelatin-coated coverslips for 7 h in the presence of various inhibitors, including OSU-03012, Akt inhibitor VIII, and calphostin, and GF109203X 
for PKC. The degraded areas on the gelatin matrix were quantified. (D and E) Dose–response curves of gelatin degradation obtained in the presence 
of increasing concentrations of OSU-03012 (D) or Akt inhibitor VIII (E) are shown. (F) Representative images of MDA-MB-231 cells treated with 10 µM 
OSU-03012 and 20 µM Akt inhibitor VIII are shown. Arrowheads denote the gelatin degradation sites. (G–J) The percentage of cells with invadopodia (G and I)   
and the relative number of invadopodia per cell (H and J) were quantified for cells treated with 10 µM OSU-03012 (G and H) or 20 µM Akt inhibitor VIII 
(I and J). (K) Cells expressing E545K or H1047R p110 were examined for gelatin degradation in the presence of 10 µM OSU-03012 or 20 µM Akt 
inhibitor VIII. Data are represented as means ± SEM of six (C, I, and J), four (E, G, H, and K), and three (D) independent determinations. *, P < 0.02; and 
**, P < 0.005 by Student’s t tests.JCB • VOLUME 193 • NUMBER 7 • 2011   1284
Guillermet-Guibert et al., 2008). In addition, it has been re-
ported that immune system function is largely dependent on p110 
and p110 (Rommel et al., 2007). Moreover, unlike PIK3CA, 
which encodes p110, cancer-specific mutations have not been 
reported for genes encoding other class I PI3Ks (Jia et al., 2009). 
Based on these findings and the specific role of p110 in invado-
podia formation, we hypothesize that p110 is a promising thera-
peutic target for the treatment of cancer invasion and metastasis 
with minimal side effects.
The PIK3CA mutations found in human cancers primarily 
occur at two hot spots: E545K in the helical domain and H1047R 
in the catalytic domain (Samuels and Ericson, 2006; Zhao and 
Vogt, 2008). These mutations are known to promote the catalytic 
activity of p110, thereby leading to constitutive activation of 
the PI3K signaling pathway (Kang et al., 2005). We determined 
that the E545K and H1047R mutations in p110 enhanced 
invadopodia-mediated ECM degradation and invasion. This find-
ing provides mechanistic insight into the role of p110 muta-
tions in cancer invasion.
Although we clearly showed that basal p110 activity is 
required for invadopodia formation, mutations of p110 are not 
sufficient  to  trigger  invadopodia  formation.  In  fact,  several 
breast cancer cell lines that contain p110 mutations, such as 
MCF-7 and T47D (Hollestelle et al., 2007), are unable to form 
that PI3K products were enriched with F-actin at the invado-
podia, as detected with the GFP-Akt PH construct. Consistent 
with these observations, Mandal et al. (2008) recently reported 
that PI3K is required for the formation of F-actin cores of invado-
podia induced by TGF- stimulation.
An important finding of the present study was that among 
the PI3K isoforms, the class I PI3K catalytic subunit p110 is 
specifically involved in invadopodia formation. We showed that 
pharmacological  inhibition  of  p110  blocked  invadopodia-
mediated ECM degradation and invasion in human breast cancer 
cell lines. Several inhibitors that target PI3Ks are currently being 
tested in clinical trials for the treatment of human cancers   
(Engelman, 2009). However, these broad-spectrum PI3K inhibi-
tors can cause significant side effects caused by the multiple 
roles of the PI3K signaling pathway in basic cellular functions. 
Therefore, current research is extensively focused both on under-
standing the isoform-specific functions of PI3Ks and on devel-
oping isoform-specific inhibitors of the PI3K family proteins 
(Zhao and Vogt, 2008; Engelman, 2009; Jia et al., 2009).
Recent studies have delineated distinct functions of class I 
PI3K isoforms (Engelman, 2009; Jia et al., 2009). The p110 
subunit was shown to predominantly mediate PI3K signaling activ-
ity in receptor tyrosine kinase signal transduction, whereas p110 
responds to G protein–coupled receptors (Zhao et al., 2006; 
Figure 7.  Expression of Akt constructs affects invadopodia formation. (A) MDA-MB-231 cells stably expressing HA-tagged wild-type (WT), kinase-dead (KD), 
or myristoylated constitutively active (Myr) Akt1 were analyzed by immunoblotting. (B–D) Cells stably expressing the Akt constructs were cultured on fluores-
cent gelatin-coated coverslips for 7 h and stained for F-actin. Degraded areas on the gelatin matrix (B), the percentage of cells with invadopodia (C), and 
the number of invadopodia per cell (D) were quantified. Data are represented as means +SEM of six (B) and four to eight (C and D) independent determi-
nations. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 by Student’s t tests. (E) Representative images of cells expressing the Akt constructs. Arrowheads 
denote the gelatin degradation sites. (F) Cells expressing WT or Myr Akt1 were cultured on fluorescent gelatin matrices for 3 h and stained with anti-HA 
antibody and phalloidin. Insets are magnified images of the boxed regions. Arrowheads denote localization of the HA signals at invadopodia.1285 PI3-kinase p110 regulates invadopodia formation • Yamaguchi et al.
Liu et al., 2006). Further studies are necessary to elucidate the 
exact mechanisms underlying the regulation of invadopodia for-
mation by the p110–PDK1–Akt pathway.
In conclusion, our results strongly suggest that the PI3K 
signaling pathway mediated by p110 is a critical regulator of 
invadopodia-mediated invasion of human breast cancer cells. 
These findings identified a new cellular function of the well-
known oncogene product p110 and provided new insights into 
the molecular mechanisms of invadopodia formation and can-
cer cell invasion.
Materials and methods
Cell culture
Human breast cancer cell lines MDA-MB-231, BT-549, and Hs578T were 
obtained from the American Type Culture Collection. MDA-MB-231 cells 
were maintained in a 1:1 mixture of high glucose-DME and RPMI 1640 
supplemented with 10% FBS, 10 U/ml penicillin, and 10 µg/ml streptomy-
cin. BT-549 and Hs578T cells were maintained in RPMI 1640 and DME, 
respectively, supplemented as described previously in this paragraph.
Antibodies, reagents, and constructs
Alexa  dyes,  fluorescently  labeled  phalloidin,  and  secondary  antibodies 
were purchased from Invitrogen. LY294002, wortmannin, anti-p110, anti-
p110, anti-ERK, and anti-Akt antibodies were purchased from Cell Signal-
ing Technology. The anti-p110 antibody, calphostin, and Akt inhibitor VIII 
were purchased from EMD. Recombinant human EGF was purchased from 
Millipore. The anti-HA antibody was purchased from Covance. PIK-75 and 
IC87114 were purchased from Symansis. TGX-221 was purchased from 
Cayman Chemical. OSU-03012 was purchased from Echelon Biosciences. 
GF109203X was purchased from Enzo Life Sciences. The anti–-actin anti-
body, gelatin, and other chemicals were purchased from Sigma-Aldrich. For 
GFP-Akt-PH domain constructs, the cDNA that encoded the mouse Akt-PH 
domain (1–111 aa) was subcloned into the pEGFP-C1 vector (Takara Bio 
Inc.). pBabe-puro constructs for HA-tagged WT, E545K, and H1047R forms 
of p110 were provided by J. Zhao (Harvard Medical School, Boston, MA; 
Zhao et al., 2005) through Addgene. pLNCX constructs for HA-tagged WT, 
KD, and constitutively active Myr forms of Akt were provided by W. Sellers 
(Harvard Medical School, Boston, MA; Ramaswamy et al., 1999) through 
Addgene. The mutagenesis basal kit (PrimeSTAR; Takara Bio Inc.) and site-
directed  mutagenesis  kit  (QuickChange  Lightning;  Agilent  Technologies) 
were used to generate the Akt-PH domain R25C mutant and Akt1 E17K and 
E40K mutants.
Plasmid transfection, retroviral infection, lentiviral infection,  
and generation of stable cell lines
MDA-MB-231 cells were transfected with the indicated plasmids using Lipo-
fectamine 2000 (Invitrogen) or Lipofectamine LTX (Invitrogen) according to 
the manufacturer’s instructions. To generate stable cell lines, transfected 
cells were selected with G418 at 1 mg/ml, and resistant clones were iso-
lated. For retroviral infection, cDNAs were inserted into the pMXs-IP or pLNCX 
vector, and recombinant retroviruses were produced with the Platinum-A 
packaging cell line as previously described (Kitamura et al., 2003). In 
brief, Platinum-A cells were transfected with the retroviral constructs using 
Lipofectamine 2000, and the medium was changed at 1 d after transfec-
tion. Culture medium containing recombinant retroviruses was collected at 
2 d after transfection and filtered through a 0.45-µm filter. Cells were imme-
diately infected with the recombinant retroviruses in the presence of 5 µg/ml 
polybrene for 1 d and then selected with 1 µg/ml puromycin or 1 mg/ml 
G418. Control and p110 shRNA lentiviral particles were purchased from 
Santa Cruz Biotechnology, Inc. Lentiviral infection was performed accord-
ing to the manufacturer’s instructions, and infected cells were selected with 
1 µg/ml puromycin.
Immunofluorescence analysis
Cells were fixed in 4% paraformaldehyde for 15 min and permeabi-
lized with 0.1% Triton X-100 for 5 min. To detect the localization of 
GFP-Akt PH construct and PDK1, cells were fixed and permeabilized in 
4% paraformaldehyde, 0.1% glutaraldehyde, and 0.075 mg/ml saponin 
for 1 h at 37°C. The cells were blocked in 1% BSA and 1% goat serum for 
30 min. The cells were incubated with primary antibodies for 1 h and then 
invadopodia  as  reported  previously  (Coopman  et  al.,  1998; 
Yamaguchi et al., 2009). Therefore, it is likely that activation of 
other factors and/or signaling pathways trigger invadopodia for-
mation, and the concurrent activation of p110 by mutations 
may act as a positive modulator in this process. This concept 
is supported by the fact that activating p110 mutations are 
preferentially observed in invasive tumors (Saal et al., 2005; 
Maruyama et al., 2007) and often associated with other altera-
tions, such as ERBB2 overexpression and K-ras mutations (Oda 
et al., 2008).
In the present study, we demonstrated, for the first time, 
that PDK1 and Akt are involved in invadopodia formation. 
Importantly, knockdown and pharmacological inhibition of Akt 
or PDK1 abolished the enhanced invadopodia formation in-
duced by E545K and H1047R p110. Previous studies have 
shown that PDK1 and Akt are overexpressed and/or mutated in 
various human cancers and have implicated these proteins in 
cancer invasion and metastasis (Xie et al., 2006; Pinner and Sahai, 
2008; Liu et al., 2009; Sheng et al., 2009). Therefore, our find-
ings may provide a further rationale for targeting PDK1 and Akt 
in addition to p110 in the development of antiinvasion and 
antimetastasis strategies.
Additional evidence that Akt is required for invadopodia 
formation was provided by the overexpression of WT and KD 
forms of Akt. Unexpectedly, however, overexpression of consti-
tutively active forms of Akt markedly blocked invadopodia for-
mation. Because we observed that Akt localized to invadopodia, 
site-specific  and  controlled  activation  of Akt  by  p110  and 
PDK1 may be required for proper invadopodia formation and 
cancer invasion. In agreement with this idea, the constitutively 
active form of Akt was shown to inhibit the invasion of breast 
cancer cells both in vitro and in vivo (Hutchinson et al., 2004; 
Figure 8.  A model of the function of PI3K signaling in invadopodia forma-
tion and cell invasion. p110 that is activated downstream of growth factor 
receptors produces the signaling lipid PI(3,4,5)P3 to regulate invadopodia 
formation and cancer cell invasion. PI(3,4)P2 that is generated via dephos-
phorylation of PI(3,4,5)P3 by synaptojanin-2 (SJ2) may regulate invadopo-
dia formation through the Tks5/N-WASP axis in parallel with PI(3,4,5)P3. 
PDK1 and Akt are activated by both PI(3,4,5)P3 and PI(3,4)P2 and act as 
mediators of the PI3K signaling pathway for invadopodia formation.JCB • VOLUME 193 • NUMBER 7 • 2011   1286
Invasion assay
Matrigel  invasion  assay  was  performed  with  a  tumor  invasion  system   
(BioCoat: BD) composed of 24-multiwell inserts plates (8-µm pore size; Fal-
con FluoroBlok; BD) coated with Matrigel matrix (BD). The insert wells were 
rehydrated with 500 µl PBS for 2 h at 37°C. Cells were labeled with green   
5-chloromethylfluorescein  diacetate  (CellTracker;  Invitrogen)  and  resus-
pended at 1 × 10
5/ml in serum-free medium. 500 µl of the labeled cell sus-
pension was added to the upper chambers, and 750 µl of growth medium 
containing 10% FBS was added to the lower chambers as a chemoattrac-
tant. After 24 h of incubation at 37°C, cells that invaded onto the lower sur-
face  of  the  filters  were  directly  imaged  with  a  confocal  microscope 
(IX81-ZDC-DSU) using a 10× objective (UPLFLN 10×2PH; NA 0.3). Invaded 
cells were counted in five randomly selected fields per filter, the mean num-
ber of control cells was set to 100%, and the relative values of other cells 
were then calculated in each experiment.
Statistical analysis
Data are representative of at least three independent experiments. Statisti-
cal analysis was performed using Student’s t tests. All p-values shown are 
versus control cells.
Online supplemental material
Fig. S1 shows the effects of PI3K inhibitors LY294002 and Wortmannin on in-
vadopodia formation. Fig. S2 shows the expression levels of GFP-Akt-PH and 
the localization of GFP in MDA-MB-231 cells. Fig. S3 shows RT-PCR analysis 
of the expression of PI3K and Akt isoforms in MDA-MB-231 cells. Fig. S4 
shows the effects of p110 knockdown and PIK-75 treatment on invado-
podia formation and localization of PDK1 and Akt at invadopodia in human 
breast cancer cell lines. Fig. S5 shows the effects of the expression of E17K 
and E40K Akt1 constructs on invadopodia formation. Table S1 and Table S2 
show siRNA and primer sequences, respectively, used in this study. Video 1 
and Video 2 show disassembly of invadopodia by LY294002 treatment in 
MDA-MB-231 cells expressing GFP-actin and Venus-cortactin, respectively. 
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.201009126/DC1.
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with fluorophore-conjugated secondary antibodies and phalloidin (Invit-
rogen) for 30 min. Samples were observed with a confocal microscope 
(IX81-ZDC-DSU;  Olympus)  equipped  with  a  cooled  charge-coupled   
device  camera  (ORCA-ER;  Hamamatsu  Photonics),  and  the  imaging   
system  was  driven  by  MetaMorph  software  (Universal  Imaging).  All   
images were acquired using 60× (PLAPON60×O; NA 1.42) or 100× 
(UPLSAPO100×O; NA 1.4) oil objectives. Images were analyzed and 
processed with various software packages, including MetaMorph, ImageJ 
(version 1.41o; National Institutes of Health), and Photoshop (CS4; Adobe).
Time-lapse microscopic analysis
In brief, time-lapse series of cells were taken at 37°C using the aforemen-
tioned  microscope  (IX81-ZDC-DSU)  equipped  with  a  humidified  CO2 
chamber. Digital images were converted in ImageJ 1.41o, and the fluores-
cence intensity of GFP-actin at the invadopodia was calculated.
RNAi
All RNAi experiments were performed using Stealth RNAi molecules (Invit-
rogen). The Stealth RNAi molecules used in this study are shown in Table S1. 
Cells were transfected with 30 nM siRNA using Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s instructions. The cells were   
cultured for 48–72 h and used for invadopodia formation assay and 
other assays.
RT-PCR
Total  RNA  was  isolated  with  an  RNeasy  Plus  Mini  kit  (QIAGEN).   
Template cDNAs were synthesized with SuperScript III (Invitrogen). Quanti-
tative RT-PCR was performed with a quantitative PCR mix (THUNDERBIRD; 
TOYOBO) in a real-time PCR detection system (CFX96; Bio-Rad Labora-
tories).  For  standard  PCR  amplification,  DNA  polymerase  (KOD-plus; 
TOYOBO)  and  PCR  beads  (puReTaq  Ready-To-Go;  GE  Healthcare)   
were used. The sequences of primer pairs used in this study are shown   
in Table S2.
Immunoblotting
Cells  were  washed  with  ice-cold  PBS  twice  before  direct  extraction  in   
SDS-PAGE sample buffer or lysis in a buffer containing 25 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, and a protease inhibitor cocktail (Roche). The samples were re-
solved by SDS-PAGE, transferred to polyvinylidene difluoride membranes, 
and blocked with 5% nonfat dried milk. The membranes were incubated 
first with primary antibodies for 1 h and then with peroxidase-conjugated 
secondary antibodies for 30 min. The antibodies were diluted in immuno-
reaction enhancer solution (Can Get Signal; TOYOBO). Immunoreactive 
bands were detected using an ECL-plus kit (GE Healthcare).
Invadopodia assay
Fluorescent matrix-coated dishes were prepared as previously described 
(Bowden et al., 2001). Gelatin was labeled with TRITC in a buffer contain-
ing 40 mM NaCl and 50 mM Na2B4O7, pH 9.3, and unbound dyes were 
removed by extensive dialysis against PBS at 37°C. 12-mm circular cover-
slips were coated with 100 µl of 25-mg/ml fluorescent gelatin and 20-mg/ml 
sucrose in PBS and then cross-linked with 0.5% glutaraldehyde on ice for 
15 min followed by 30 min at room temperature. After extensive washing 
with PBS, the coverslips were treated with 5 mg/ml sodium borohydrate for 
5 min to quench autofluorescence of residual glutaraldehyde. The cover-
slips were then sterilized with 70% ethanol for 15 min. MDA-MB-231 cells 
were cultured on the gelatin-coated coverslips for 3–7 h. To quantitate the 
gelatin degradation activity of invadopodia, we calculated the degrada-
tion area observed in images with the ImageJ 1.41o software and normal-
ized the measurements to the total number of cells in each image. 10 randomly 
selected fields, usually containing 30–50 cells in total, were imaged with 
a 60× objective and analyzed for each experiment. The values of control 
cells were set to 100%, and the relative values of other cells were then 
calculated accordingly. The relative number of invadopodia and the per-
centage of cells with invadopodia were also calculated from the micros-
copy images.
EGF stimulation
Cells were serum-starved overnight in medium containing 0.35% BSA 
and stimulated with 8 nM EGF for 10 min at 37°C. The cells were sub-
sequently washed twice with ice-cold PBS and lysed with a lysis buffer 
containing 50 mM Tris-HCl, pH 7.5, 1% NP-40, 2 mM EDTA, 100 mM 
NaCl, 1 mM sodium orthovanadate, and a protease inhibitor cocktail. 
The lysates were separated from cell debris by centrifugation and used 
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